Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data - PubMed
6 hours ago
- #meta-analysis
- #pulmonary arterial hypertension
- #sotatercept
- Sotatercept reduced clinical worsening or death by 77% and prolonged event-free survival by about 40 weeks in patients with PAH.
- It improved WHO functional class (40.3% vs 24.3%) and increased 6-minute walk distance by 30.27 meters.
- Pulmonary vascular resistance declined significantly (-247 dyn·s·cm-5).
- Serious adverse events were slightly less frequent, but bleeding events, epistaxis, and telangiectasia were more common.
- Sotatercept is effective as an add-on therapy for PAH with an acceptable safety profile, though caution is needed for bleeding risks.